Technical Analysis for CERS - Cerus Corporation
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 1.86 | -2.62% | -0.05 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Resistance | Bearish | -2.62% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 6 hours ago |
Possible NR7 | about 8 hours ago |
2x Volume Pace | about 12 hours ago |
1.5x Volume Pace | about 12 hours ago |
3x Volume Pace | about 12 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Cerus Corporation Description
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Coronavirus Hematology Medical Products Viruses Blood Transfusion Medicine Blood Cells Platelet Red Blood Cell Coagulation System Blood Products Blood Transfusion Fusion Products Whole Blood
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.08 |
52 Week Low | 1.21 |
Average Volume | 1,319,708 |
200-Day Moving Average | 1.98 |
50-Day Moving Average | 2.06 |
20-Day Moving Average | 2.17 |
10-Day Moving Average | 2.12 |
Average True Range | 0.16 |
RSI (14) | 37.89 |
ADX | 15.85 |
+DI | 18.49 |
-DI | 27.78 |
Chandelier Exit (Long, 3 ATRs) | 2.11 |
Chandelier Exit (Short, 3 ATRs) | 2.33 |
Upper Bollinger Bands | 2.45 |
Lower Bollinger Band | 1.88 |
Percent B (%b) | -0.03 |
BandWidth | 26.40 |
MACD Line | -0.04 |
MACD Signal Line | 0.01 |
MACD Histogram | -0.0503 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.97 | ||||
Resistance 3 (R3) | 1.98 | 1.95 | 1.95 | ||
Resistance 2 (R2) | 1.95 | 1.93 | 1.95 | 1.94 | |
Resistance 1 (R1) | 1.91 | 1.91 | 1.90 | 1.90 | 1.94 |
Pivot Point | 1.88 | 1.88 | 1.88 | 1.88 | 1.88 |
Support 1 (S1) | 1.84 | 1.86 | 1.83 | 1.83 | 1.78 |
Support 2 (S2) | 1.81 | 1.84 | 1.81 | 1.78 | |
Support 3 (S3) | 1.77 | 1.81 | 1.77 | ||
Support 4 (S4) | 1.76 |